Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator initiated, prospective, randomized, controlled study in order to evaluate the effect of anti-thymocyte globulin (Fresenius ATG) on engraftment, graft versus host disease (GVHD) and graft versus leukemia (GVL) effect in haplo-identical allogeneic haematopoietic stem-cell transplantation.

Trial Profile

An investigator initiated, prospective, randomized, controlled study in order to evaluate the effect of anti-thymocyte globulin (Fresenius ATG) on engraftment, graft versus host disease (GVHD) and graft versus leukemia (GVL) effect in haplo-identical allogeneic haematopoietic stem-cell transplantation.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2011

At a glance

  • Drugs Antithymocyte globulin (Primary)
  • Indications Graft-versus-host disease; Leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2011 Actual end date (1 Sep 2010) added as reported by ClinicalTrials.gov.
    • 01 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jun 2010 Planned end date changed from 1 Jan 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top